Curative one-shot systemic virotherapy in murine myeloma
Current therapy for multiple myeloma is complex and prolonged. Antimyeloma drugs are combined in induction, consolidation and/or maintenance protocols to destroy bulky disease, then suppress or eradicate residual disease. Oncolytic viruses have the potential to mediate both tumor debulking and resid...
Main Authors: | Naik, Shruthi, Nace, Rebecca, Federspiel, Mark J., Barber, Glen N., Peng, Kah-Whye, Russell, Stephen J. |
---|---|
Format: | Online |
Language: | English |
Published: |
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411853/ |
Similar Items
-
Mathematical Model for Radial Expansion and Conflation of Intratumoral Infectious Centers Predicts Curative Oncolytic Virotherapy Parameters
by: Bailey, Kent, et al.
Published: (2013) -
Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV
by: Yarde, Danielle N., et al.
Published: (2013) -
Potent systemic therapy of Multiple Myeloma utilizing Oncolytic Vesicular stomatitis virus coding for Interferon-beta
by: Naik, Shruthi, et al.
Published: (2012) -
ONCOLYTIC VIROTHERAPY
by: Russell, Stephen J, et al.
Published: (2012) -
Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy
by: Miller, Amber, et al.
Published: (2014)